Phase III clinical trial of vetcotozumab completes patient enrollment
February 9, 2026
Source: drugdu
32
On the morning of February 9th, China Biopharmaceutical announced on the Hong Kong Stock Exchange that its wholly-owned subsidiary, Lixin Pharmaceutical Technology (Shanghai) Co., Ltd., had independently developed a Class 1 innovative drug.Vitectumomarab (development code: LM-302, abbreviated as "CLDN18.2 ADC") is undergoing a Phase III registration clinical trial (LM302-03-101) for the treatment of third-line or higher CLDN18.2-positive locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma, and patient enrollment has been successfully completed. LM302 is the world's first CLDN18.2 ADC drug to complete enrollment in a Phase III registration clinical trial.
https://finance.eastmoney.com/a/202602093644922352.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- The first long-acting coagulation factor VIII, has officially entered the Chinese mainland market. February 9, 2026
- 17.9 billion yuan! A top-selling topical medication emerges. February 9, 2026
- Turnaround! Generic drug giant successfully “revived” February 9, 2026
- Novartis’s first-ever autoimmune drug has been submitted for marketing approval in China. February 9, 2026
- A world first! A serum-free rabies vaccine is about to be launched, marking a major breakthrough in safety. February 9, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
